-
Astellas Pharma Inc. et al v. Sandoz Inc. et al DC CAFC
- 1:20-cv-01589
- D. Del.
- Judge: Joseph F. Bataillon
+1
- Filed: 11/24/2020
- Closed: 06/09/2023
- Latest Docket Entry: 08/29/2023
- PACER
- Docket updated daily
3
Plaintiffs
25
Defendants
2
Accused
Products
1
Patent-in-Suit
928
Days in
Litigation
-
Astellas Pharma Inc. et al v. Sandoz Inc. et al DC CAFC
- 1:20-cv-01589
- D. Del.
- Judge: Joseph F. Bataillon
+1
- Filed: 11/24/2020
- Closed: 06/09/2023
- Latest Docket Entry: 08/29/2023
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 5 |
The pharmaceutical composition according to claim claim 1, wherein the hydrogel-forming polymer is at least one compound selected from the group consisting of polyethylene oxide, hydoxypropyl methylcellulose, and hydroxypropyl cellulose.
|
Invalid
Entry 14 |
| 20 |
A method for treating overactive bladder comprising administering the tablet according to claim 18 to a subject in need thereof.
|
Invalid
Entry 14 |
| 25 |
A tablet, comprising the pharmaceutical composition according to claim 23.
|
Invalid
Entry 14 |
-
Infringement
Windlas Biotech Ltd.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Myrbetriq® extended-release tablets, 25mgMyrbetriq® extended-release tablets, 50mg | US 10,842,780 B2 | All Asserted Claims |
Infringement
Entry 44
|
Windlas Healthcare Pvt Ltd
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Myrbetriq® extended-release tablets, 25mgMyrbetriq® extended-release tablets, 50mg | US 10,842,780 B2 | All Asserted Claims |
Infringement
Entry 44
|
